Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02559869
Other study ID # 2015P000140
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 2015
Est. completion date June 28, 2019

Study information

Verified date May 2020
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of ALS pathology, treatment targets, disease progression, and anatomical differences between different disease phenotypes. This pilot project is tailored to produce imaging tools that will allow researchers to conduct future ALS clinical trials more efficiently which may in turn impact the pace for ALS drug discovery.


Description:

In this trial, approximately 200 subjects will participate in this study from 2 Northeast ALS Consortium (NEALS) centers in the United States. Fifty (50) ALS participants will be age and gender matched to 50 participants with no known neurological disorder (healthy controls). Of these, twenty five (25) ALS participants will be age (±5 years) gender and binding affinity (TSPO) matched to 25 healthy controls.

During the enrollment period 200 participants will be screened and 100 participants will ultimately be scanned. There will be a maximum allowed time of 45 days between the screening and baseline visits (1st scan). All 100 subjects will undergo MRI scanning and clinical assessment at the Baseline Visit. Healthy control participants will have no further follow-up visits once they have completed their participation in the screening and baseline visits. Only 50 subjects from this sample will undergo PET scanning. The ALS participants will return for follow-up MRI scanning and clinical assessments every three months and follow-up PET scanning every 6 months over a 12-month period.


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date June 28, 2019
Est. primary completion date June 28, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria

Study subjects meeting all of the following criteria will be allowed to enroll in the study:

1. Male or female, aged 18 to 80

2. Medically safe to undergo MRI scans

3. Able to safely lie supine for at least 90 minutes in the opinion of the Site Investigator

4. Capable of providing informed consent and following trial procedures

5. Geographically accessible to the site

ALS subjects must also meet the following criteria:

1. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by modified El Escorial criteria

2. ALS Cognitive Behavioral Screen score >10 on the cognitive scale and/or >32 on the behavioral scale

Those ALS subjects participating in the optional lumbar puncture portion of the study must also meet the following criteria:

1. Subjects medically able to undergo lumbar puncture (LP) as determined by the investigator (i.e., no bleeding disorder, allergy to local anesthetics, a skin infection at or near the LP site, or evidence of high intracranial pressure).

For those subjects participating in the PET scan portion of the study, subjects must also meet the following criteria:

1. Medically safe to undergo PET scans

2. No prior radiation exposure that exceeds the site's current guidelines

3. No known allergy to any components of the tracer

4. Baseline ECG values are within normal range

5. Subjects must meet main study entry criteria

Exclusion Criteria

Study subjects meeting any of the following criteria during screening evaluations will be excluded from entry into the study:

1. Any contraindication to undergo MRI studies such as

1. History of a cardiac pacemaker or pacemaker wires

2. Metallic particles in the body

3. Vascular clips in the head

4. Prosthetic heart valves

5. Claustrophobia

2. Diagnosis of Parkinson's disease or Alzheimer's disease

3. Diagnosis of renal failure

4. Have active or chronic autoimmune disease (such as hepatitis or HIV), infection, or taking immunosuppressive medications such as steroids, cyclophosphamide, etc.

5. Presence of diaphragm pacing system (DPS)

6. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to SI judgment

7. Pregnant women or women currently breastfeeding

8. Anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study

In addition, any subject meeting any of the following criteria during screening evaluations will be excluded from entry into the PET portion of the study:

1. Radiation exposure that exceeds the site's current guidelines

2. Low affinity TSPO binders determined by having a Thr/Thr polymorphism in the TSPO gene (rs6971) at the Screening Visit

Women of Childbearing Potential (WOCBP) For the purposes of this study, women of child bearing potential are defined as all women who are capable of becoming pregnant, unless they meet one of the following criteria:

- 12-months post-menopausal

- Post-hysterectomy

- Surgically sterile

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
[18F] GE-180
PET Tracer Ligand

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts
United States Houston Methodist Hospital Houston Texas

Sponsors (4)

Lead Sponsor Collaborator
Massachusetts General Hospital ALS Association, Cedars-Sinai Medical Center, The Methodist Hospital System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measure & localize brain inflammation in people with ALS via [18F] GE-180 PET imaging. Aim 1 will be accomplished by obtaining [18F] GE-180 PET imaging from 25 people with ALS compared to 25 age, gender, and binding affinity matched healthy volunteers. 12 months
Primary Define anatomical, structural, and functional changes in the brain via MRI of ALS Subjects vs. Healthy Controls at Baseline Aim 1 will be accomplished by obtaining state of-the-art MRI acquisition sequences from 50 people with ALS compared to 50 MRI age- and gender-matched healthy volunteers. 12 months
Primary Determine systemic inflammatory factors that may modify the progression or other clinical or imaging correlates of ALS. Blood from 100 subjects will be studied to quantitate circulating pro- and anti-inflammatory monocyte/macrophage and T cells, with results to be correlated with neuroimaging and evaluated as potential biomarkers of disease progression. 12 months
Secondary Determine the longitudinal changes in brain inflammation in people with ALS in correlation with ALS severity and rate of progression. Clinical and [18F] GE-180 PET imaging data will be collected every 6 months from the 25 people with ALS for at least 12 months. 12 months
Secondary Determine the longitudinal changes in the anatomical, structural, and functional measures in people with ALS, and build ALS prediction models using the clinical and MRI data. Clinical and MRI data will be collected every 3 months from 50 people with ALS for at least 12 months. 12 months
See also
  Status Clinical Trial Phase
Completed NCT02365922 - Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Completed NCT01699451 - DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida
Completed NCT04577404 - Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) Phase 3
Terminated NCT03580616 - Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Completed NCT01884571 - Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT00244244 - A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS Phase 2
Active, not recruiting NCT00420719 - Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS) N/A
Completed NCT02936635 - A Study for Patients Who Completed VITALITY-ALS (CY 4031) Phase 3
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Completed NCT03645031 - Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease N/A
Completed NCT01786603 - Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT01592552 - A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
Completed NCT00403104 - Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT02424669 - Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients N/A
Completed NCT02017912 - Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS Phase 2
Completed NCT01366027 - PRISM Registry: Pseudobulbar Affect Registry Series N/A
Completed NCT00330681 - Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Phase 3
Completed NCT00876772 - Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Phase 2/Phase 3
Not yet recruiting NCT06351592 - First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) Phase 1